MedPath

LMC Diabetes & Endocrinology Ltd.

LMC Diabetes & Endocrinology Ltd. logo
🇨🇦Canada
Ownership
Holding
Established
1997-01-01
Employees
51
Market Cap
-
Website
http://www.lmc.ca

Clinical Trials

19

Active:1
Completed:12

Trial Phases

2 Phases

Phase 4:5
Not Applicable:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 4
5 (55.6%)
Not Applicable
4 (44.4%)

Real-world Effect of Switching From Intermittently-scanned to Real-time Continuous Glucose Monitoring (Switch CGM Retro)

Completed
Conditions
Diabetes Mellitus
First Posted Date
2025-05-08
Last Posted Date
2025-05-11
Lead Sponsor
LMC Diabetes & Endocrinology Ltd.
Target Recruit Count
220
Registration Number
NCT06962735
Locations
🇨🇦

LMC Diabetes & Endocrinology Ltd., Toronto, Ontario, Canada

Real-world Effects of Using Intermittently Scanned Continuous Glucose Monitoring and Pharmacist-led Coaching on the Management of Type 2 Diabetes Among Adults Not Using Insulin (REAL isCGM T2D)

Recruiting
Conditions
Type 2 Diabetes
First Posted Date
2025-02-20
Last Posted Date
2025-05-04
Lead Sponsor
LMC Diabetes & Endocrinology Ltd.
Target Recruit Count
250
Registration Number
NCT06837103
Locations
🇨🇦

LMC Diabetes & Endocrinology Ltd., Toronto, Ontario, Canada

Effect of Switching From Intermittently Scanned to Real-time Continuous Glucose Monitoring on Diabetes Management in Adults With Type 2 Diabetes (Switch CGM T2D)

Recruiting
Conditions
Type 2 Diabetes
First Posted Date
2025-02-03
Last Posted Date
2025-05-04
Lead Sponsor
LMC Diabetes & Endocrinology Ltd.
Target Recruit Count
150
Registration Number
NCT06805786
Locations
🇨🇦

LMC Diabetes & Endocrinology Ltd., Toronto, Ontario, Canada

Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease

Completed
Conditions
Type 2 Diabetes
Chronic Kidney Diseases
Interventions
Drug: GLP-1 receptor agonist
First Posted Date
2024-02-01
Last Posted Date
2024-02-01
Lead Sponsor
LMC Diabetes & Endocrinology Ltd.
Target Recruit Count
348
Registration Number
NCT06236672
Locations
🇨🇦

LMC Diabetes & Endocrinology Ltd., Toronto, Ontario, Canada

The Canadian Diabetes Prevention Program

Not Applicable
Active, not recruiting
Conditions
Diabetes type2
First Posted Date
2023-03-24
Last Posted Date
2023-03-24
Lead Sponsor
LMC Diabetes & Endocrinology Ltd.
Target Recruit Count
2174
Registration Number
NCT05784220
Locations
🇨🇦

LMC Diabetes Ltd, Toronto, Ontario, Canada

  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath